FDA Approves Innovative Cream to Treat Chronic Hand Eczema
The FDA has approved the first prescription cream for treating chronic hand eczema, offering new hope to millions affected by this persistent skin condition. Learn about this breakthrough treatment and its potential impact.
The U.S. Food and Drug Administration (FDA) has approved the first topical cream specifically designed to treat chronic hand eczema (CHE), a persistent and often debilitating skin condition. CHE is characterized by redness, itching, cracking, and inflammation on the hands and wrists, affecting about 10% of the U.S. population. Unlike atopic dermatitis, which is more common, CHE tends to be rarer but significantly impacts quality of life, particularly in individuals exposed to irritants or allergens occupationally, such as those working in cleaning, healthcare, or hairstyling industries.
The newly approved medication, Anzupgo (delgocitinib), is intended for adults with moderate-to-severe CHE who cannot or do not respond well to topical steroids. It functions by inhibiting JAK enzymes, which are involved in the inflammatory processes that trigger eczema flare-ups.
This treatment offers hope for many patients, as current options were limited and often ineffective. Studies prior to approval demonstrated that patients using Anzupgo experienced notably improved symptoms compared to placebo. Importantly, the cream does not carry the boxed warnings associated with other JAK inhibitors, making it a safer option.
Experts emphasize the significance of this approval. Dr. Linda Stein Gold from Henry Ford Health expressed optimism, citing the considerable burden CHE imposes on sufferers. Kristin Belleson, CEO of the National Eczema Association, highlighted that this development provides new hope for those whose daily lives are disrupted by the disease.
Internationally, Anzupgo has already been approved in regions including the European Union, United Kingdom, Switzerland, and the United Arab Emirates. Its availability in the U.S. marks a pivotal step in advancing treatment options for chronic hand eczema.
This milestone reflects ongoing efforts to address difficult-to-treat skin conditions and improve patient outcomes, especially for those facing persistent and recurrent symptoms.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Five Years of Success for Meningococcal B Vaccination Program
South Australia's Meningococcal B vaccination program has led to a 70% reduction in cases over five years, significantly decreasing disease and saving lives. High vaccine efficacy highlights the importance of complete immunization to protect infants and young adults from serious bacterial infections.
New Insights into Alzheimer's Disease: Tau and Amyloid-β Protein Interaction Reduces Toxicity
New research reveals that direct communication between tau and amyloid-β proteins can reduce Alzheimer's toxicity, offering promising insights for future therapies.
Understanding Dementia Risk: Why Lifestyle Factors Are Only Part of the Story
Understanding dementia risk requires recognizing the complex social, genetic, and lifestyle factors involved. Overemphasizing individual behaviors can lead to stigma and health disparities. Learn how a social, inclusive approach fosters better prevention and support.